<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991883</url>
  </required_header>
  <id_info>
    <org_study_id>MFS</org_study_id>
    <nct_id>NCT04991883</nct_id>
  </id_info>
  <brief_title>Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities</brief_title>
  <acronym>MFS</acronym>
  <official_title>Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities: Diagnostic and Prognostic Impact</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single institution case series review with a histological diagnosis of mixofibrosarcoma of&#xD;
      the extremities from 01 Jan 1993 to 01 Dec 2017.&#xD;
&#xD;
      The study will exam all the clinical, radiological, histological and immunohistochemical&#xD;
      features of this tumour in all samples and in a limited serie of cases the presence of&#xD;
      mutation of 50 genes cancer related.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>at baseline (Day0)</time_frame>
    <description>identify patients with different risk classes in terms of disease-free survival (local and systemic recurrence).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>at baseline (Day0)</time_frame>
    <description>identify patients with different risk classes in terms of overall survival.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sarcoma,Soft Tissue</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>case series review of clinical and histological data</intervention_name>
    <description>We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of Mixofibrosarcoma treated at the Rizzoli Institute from 1&#xD;
        January 1993 up to 01 December 2017&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients treated at Rizzoli Institute from 01 Jan 1993 to 01 Dec 2017&#xD;
&#xD;
          2. Diagnosis of mixofibrosarcoma of extremities&#xD;
&#xD;
          3. Histological slides/formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from&#xD;
             archive available to perform the histology analysis and molecular analysis&#xD;
&#xD;
          4. Enough tumor biobanked material available for molecular analysis&#xD;
&#xD;
          5. Presence of the biobank signed informed consent&#xD;
&#xD;
          6. Written informed consent prior to any study-specific analysis and/or data collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Patients with histological diagnosis different from mixofibrosarcoma of extremities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Bianchi, MD</last_name>
    <phone>0516366</phone>
    <phone_ext>523</phone_ext>
    <email>giuseppe.bianchi@ior.it</email>
  </overall_contact>
  <results_reference>
    <citation>Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996 Apr;20(4):391-405.</citation>
    <PMID>8604805</PMID>
  </results_reference>
  <results_reference>
    <citation>Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010 Mar;251(3):506-11. doi: 10.1097/SLA.0b013e3181cf87fa.</citation>
    <PMID>20130465</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamaguchi T, Hasegawa T, Yamashita T. MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol. 2008 Dec;37(12):1085-90. doi: 10.1007/s00256-008-0542-4. Epub 2008 Jul 16.</citation>
    <PMID>18629459</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mixofibrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT04991883/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

